Stoke Therapeutics, Inc. STOK Interest Income (Expense), Nonoperating
Interest Income (Expense), Nonoperating at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s interest income (expense), nonoperating?
- Stoke Therapeutics, Inc. (STOK) reported interest income (expense), nonoperating of $3.4M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s interest income (expense), nonoperating changed year-over-year?
- Stoke Therapeutics, Inc.'s interest income (expense), nonoperating increased by 17.6% year-over-year, from $2.89M to $3.4M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s interest income (expense), nonoperating?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s interest income (expense), nonoperating has grown at a 227.2% compound annual growth rate (CAGR), from $120K to $13.76M.